Revised PBS restrictions for fluticasone propionate 50 micrograms per dose inhalers
Page last updated: 1 April 2023
On 1 April 2023, changes have been made to the General Schedule (Section 85) listing, population criteria and treatment criteria for fluticasone propionate 50 microgram/actuation inhalation, 120 actuations (Axotide Junior®, Flixotide Junior®) indicated for the prophylactic management of asthma.
From 1 April 2023, fluticasone propionate 50 microgram per dose, 120 actuations (Axotide Junior®, Flixotide Junior®) listing
- is restricted to patients aged under six years
- is amended to an Authority Required (telephone or electronic)
- requires initiation by a respiratory physician or a paediatrician.
The PBS listing for this medicine has been amended on 1 April 2023 to reflect these changes. Further information regarding these changes is available in the summary document ‘Revised PBS restrictions for fluticasone propionate50 micrograms per dose inhalers’ (PDF 97KB) (Word 29KB).
